首頁
Aerie Pharmaceuticals

8月 2026Aerie Pharmaceuticals的市場佔有率分析

our mission is to provide innovative vision products that enhance quality of life by helping people see better. from vision research to eye health, learn more at alcon.com.

健康 > 生物技術和製藥

域名aeriepharma.com

成立年份2005

僱員201 - 500

年度營收$100M - $200M

Aerie Pharmaceuticals

Aerie Pharmaceuticals（包含公司地區）

aeriepharma.com

查看更多網站流量與參與度資訊

Aerie Pharmaceuticals截至 8月 2026 的總收入為 100M - 200M

Aerie Pharmaceuticals 熱門網域產生的總收入

Aerie Pharmaceuticals 熱門網域 3 年內的總收入

Aerie Pharmaceuticals 熱門網域的總收入

aeriepharma.com100M - 200M

透過銷售情報查看更多內容

Aerie Pharmaceuticals的熱門網域總造訪量

了解Aerie Pharmaceuticals市場觸達率與潛在市場影響力。

過去 3 個月的訪問總量

無可顯示數據

Aerie Pharmaceuticals的熱門網域平均造訪時長

分析Aerie Pharmaceuticals參與度指標。

過去 3 個月平均造訪時長

無可顯示數據

Aerie Pharmaceuticals的熱門網域平均頁面瀏覽量

了解Aerie Pharmaceuticals如何保持使用者的參與度、培養其興趣，並鼓勵他們採取下一步。

過去 3 個月平均頁面瀏覽量

無可顯示數據

Aerie Pharmaceuticals按網域劃分的熱門競爭對手

8月 2026的熱門類似網站，依相似度排名

parmed.com公司名ParMed Pharmaceuticals僱員51 - 200總部美國, 紐約, Niagara Falls年度營收$15M - $25M訪問總量123.7K健康 > 生物技術和製藥

使用的熱門技術Aerie Pharmaceuticals

这些是Aerie Pharmaceuticals顶级域名使用的行业网站技术

小工具 (4)

Twemoji

音訊視訊媒體 (2)

YouTube

內容管理系統 (2)

WordPress

轉換與分析 (1)

Google Analytics

更多技術

7

檢視所有

新聞與訊號來自Aerie Pharmaceuticals

透過 Similarweb 銷售訊號提醒，每當目標受眾出現新的機會或威脅時，你就會收到每日更新的已識別購買訊號。

新聞Alcon Components Limited acquires Aerie Pharmaceuticals Inc.Alcon acquired the ophthalmic supplier Aerie Pharmaceuticals for £658m ($770m), adding to its expansion into the ophthalmic eye drop space and to broaden its research and development (R&D) capabilities.

新聞Alcon Switzerland SA acquired Aerie Pharmaceuticals Inc for $770M on Aug 1st '22.That includes Aerie Pharmaceuticals (NASDAQ: AERI), which recently announced it’s being bought by Switzerland-based Alcon (NYSE: ALC) for around $770 million.

新聞Aerie Pharmaceuticals Inc hired Peter F. Lang as Chief Financial Officer on Mar 18th '22.Aerie Pharmaceuticals, Inc. (NASDAQ: AERI), a pharmaceutical company focused on the discovery, development and commercialization of first-in-class ophthalmic therapies, today announced that Peter F. Lang will join the Company as Chief Financial Officer, effective March 18, 2022.